АДЪЮВАНТНАЯ ХИМИОТЕРАПИЯ В ЛЕЧЕНИИ БОЛЬНЫХ РАКОМ ЖЕЛЧНОГО ПУЗЫРЯ, gemcitabine, mitomycin, cisplatin, 
capecitabine, epirubicin, and oxaliplatin. This article provides
 Predictive value of vascular endothelial growth factor receptor type 2 in triple-negative breast cancer patients treated with neoadjuvant chemotherapyZavyalova, Marina V., 
Tarabanovskaya, Natalia A., 
Dronova, Tatyana, 
Krakhmal, Nadezhda V., 
Slonimskaya, Elena M., 
Kzhyshkowska, Julia G., 
Choynzonov, Evgeny L., 
Cherdyntseva, Nadezhda V., 
Babyshkina, Nataliya , and cyclophosphamide (FAC) or cyclophosphamide, adriamycin, and 
capecitabine (CAX) between 2007 and 2013. VEGFR2